Log in

TSE:RVX - Resverlogix Stock Price, Forecast & News

+0.05 (+3.91 %)
(As of 02/24/2020 07:12 AM ET)
Today's Range
Now: C$1.33
50-Day Range
MA: C$1.26
52-Week Range
Now: C$1.33
Volume24,500 shs
Average Volume73,713 shs
Market CapitalizationC$278.17 million
P/E Ratio8.99
Dividend YieldN/A
Resverlogix Corp., a development stage company, develops small molecule therapeutics for bromodomain and extra-terminal (BET) inhibitior in the United States and Canada. It is developing apabetalone (RVX-208), a small molecule selective BET bromodomain inhibitor that is in Phase III clinical trials for the treatment of patients with cardiovascular diseases, diabetes mellitus, chronic kidney diseases, renal diseases, peripheral artery diseases, orphan diseases, and neurodegenerative diseases. The company is headquartered in Calgary, Canada.

Industry, Sector and Symbol

Industry Biotechnology



Sales & Book Value

Annual SalesN/A
Cash FlowC$0.00 per share
Book ValueC($0.39) per share



Market CapC$278.17 million
Next Earnings Date3/20/2020 (Estimated)
OptionableNot Optionable

Receive RVX News and Ratings via Email

Sign-up to receive the latest news and ratings for RVX and its competitors with MarketBeat's FREE daily newsletter.

Resverlogix (TSE:RVX) Frequently Asked Questions

What is Resverlogix's stock symbol?

Resverlogix trades on the Toronto Stock Exchange (TSX) under the ticker symbol "RVX."

When is Resverlogix's next earnings date?

Resverlogix is scheduled to release their next quarterly earnings announcement on Friday, March 20th 2020. View Earnings Estimates for Resverlogix.

What is the consensus analysts' recommendation for Resverlogix?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Resverlogix in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Resverlogix.

Has Resverlogix been receiving favorable news coverage?

Media stories about RVX stock have trended very negative on Monday, InfoTrie reports. The research group identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Resverlogix earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Resverlogix.

Who are some of Resverlogix's key competitors?

What other stocks do shareholders of Resverlogix own?

Who are Resverlogix's key executives?

Resverlogix's management team includes the folowing people:
  • Mr. Donald J. McCaffrey, Co-Founder, Pres, CEO & Chairman
  • Mr. Aaron Bradley Cann CA, CPA, CBV, Chief Financial Officer
  • Mr. Kenneth Eugene Lebioda BA, Sr. VP of Bus. & Corp. Devel.
  • Dr. Jan O. Johansson, Sr. VP of Medical Affairs
  • Dr. Michael Sweeney, Sr. VP of Clinical Devel. (Age 58)

How do I buy shares of Resverlogix?

Shares of RVX and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Resverlogix's stock price today?

One share of RVX stock can currently be purchased for approximately C$1.33.

How big of a company is Resverlogix?

Resverlogix has a market capitalization of C$278.17 million. View Additional Information About Resverlogix.

What is Resverlogix's official website?

The official website for Resverlogix is http://www.resverlogix.com/.

How can I contact Resverlogix?

Resverlogix's mailing address is 300-4820 Richard Rd SW, CALGARY, AB T3E 6L1, Canada. The biotechnology company can be reached via phone at +1-403-2549252.

MarketBeat Community Rating for Resverlogix (TSE RVX)

Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  286 (Thanks for Voting!)
Underperform Votes:  114 (Thanks for Voting!)
Total Votes:  400
MarketBeat's community ratings are surveys of what our community members think about Resverlogix and other stocks. Vote "Outperform" if you believe RVX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RVX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel